脑机接口概念拉升，国家医保局支持脑机接口等进入临床并收费

Core Viewpoint - The news highlights a significant rise in brain-computer interface (BCI) concept stocks, driven by new pricing mechanisms introduced by the National Healthcare Security Administration (NHSA) to support innovation in pharmaceuticals and medical devices [1] Group 1: Market Reaction - BCI-related stocks surged, with companies like Innovation Medical nearing a trading limit increase, and others such as Aipeng Medical, Sanbo Brain Science, Entropy Technology, Qisheng Technology, and Yanshan Technology also experiencing gains [1] Group 2: Policy Changes - The NHSA has established a new pricing mechanism for newly launched drugs, adding over 100 pricing items related to new medical technologies [1] - Specific pricing items for neurological projects include "brain-computer interface implantation fees" and "brain-computer interface adaptation fees," facilitating rapid clinical application and reimbursement once the technology is approved [1] - For ear, nose, and throat projects, pricing items like "cochlear implant fees" and "speech device installation fees" have been standardized to encourage healthcare institutions to assist more patients in communication [1] - In radiation therapy, pricing items for "proton therapy" and "heavy ion therapy" have been set to promote the clinical application of advanced medical equipment [1]